Kazakhstan allocates 5 billion tenge for domestic cancer drug development amid audit concerns

Kazakhstan has allocated 5 billion tenge for the development of a domestic cancer drug. However, the Supreme Audit Chamber found insufficient evidence of production readiness. Concerns were raised about payment procedures and the early release of funds to research organizations.

Read the full article at Stan.kz →

Headline and summary written by daryo. The full report belongs to Stan.kz.